{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:27:46Z","timestamp":1789014466688,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12185-020-03013-6","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T13:02:56Z","timestamp":1602334976000},"page":"219-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR"],"prefix":"10.1007","volume":"113","author":[{"given":"Naoki","family":"Takezako","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"3013_CR1","first-page":"A335","volume":"18","author":"K Yamabe","year":"2015","unstructured":"Yamabe K, Inoue S, Hiroshima C. Epidemiology and burden of multiple myeloma in Japan: a systematic review. Value Health. 2015;18:A335\u2013A766.","journal-title":"Value Health."},{"key":"3013_CR2","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1080\/10428194.2018.1427858","volume":"59","author":"D Tan","year":"2018","unstructured":"Tan D, Lee JH, Chen W, Shimizu K, Hou J, Suzuki K, et al. Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Leuk Lymphoma. 2018;59:2305\u201317.","journal-title":"Leuk Lymphoma."},{"key":"3013_CR3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia\u2014an Asian myeloma network study. Am J Hematol. 2014;89:751\u20136.","journal-title":"Am J Hematol"},{"key":"3013_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2146\/ajhp130281","volume":"72","author":"A McBride","year":"2015","unstructured":"McBride A, Klaus JO, Stockerl-Goldstein K. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. Am J Health Syst Pharm. 2015;72:353\u201360.","journal-title":"Am J Health Syst Pharm"},{"key":"3013_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors\u2014molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18:947\u201361.","journal-title":"J Cell Mol Med"},{"key":"3013_CR6","unstructured":"Kyprolis\u00ae. Japanese package insert (November 2019; Edition 1) https:\/\/www.info.pmda.go.jp\/go\/pack\/4291433D1026_1_04\/. Accessed May 2020."},{"issue":"27\u201338","key":"3013_CR7","first-page":"10","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(27\u201338):10.","journal-title":"Lancet Oncol"},{"key":"3013_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"M Dimopoulos","year":"2017","unstructured":"Dimopoulos M, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327\u201337.","journal-title":"Lancet Oncol"},{"key":"3013_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12185-016-2070-7","volume":"104","author":"S Iida","year":"2016","unstructured":"Iida S, Tobinai K, Taniwaki M, Shumiya Y, Nakamura T, Chou T. Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol. 2016;104:596\u2013604.","journal-title":"Int J Hematol"},{"key":"3013_CR10","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1111\/cas.14139","volume":"110","author":"S Iida","year":"2019","unstructured":"Iida S, Watanabe T, Matsumoto M, Suzuki K, Sunami K, Ishida T, et al. Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: a phase 1\/2 study. Cancer Sci. 2019;110:2924\u201332.","journal-title":"Cancer Sci"},{"key":"3013_CR11","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","volume":"127","author":"JR Berenson","year":"2016","unstructured":"Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, et al. CHAMPION-1: a phase 1\/2 study of once weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127:3360\u20138.","journal-title":"Blood"},{"key":"3013_CR12","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1111\/cas.13753","volume":"109","author":"D Maruyama","year":"2018","unstructured":"Maruyama D, Tobinai K, Chou T, Taniwaki M, Shumiya Y, Iida S. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: a phase 1 and PK\/PD trial. Cancer Sci. 2018;109:3245\u201352.","journal-title":"Cancer Sci"},{"key":"3013_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953\u201364.","journal-title":"Lancet Oncol."},{"key":"3013_CR14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"3013_CR15","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"3013_CR16","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1002\/cam4.2945","volume":"9","author":"P Moreau","year":"2020","unstructured":"Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J, et al. Once-weekly (70 mg\/m2) vs twice-weekly (56 mg\/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.R, and CHAMPION-1 trials. Cancer Med. 2020;9:2989\u201396.","journal-title":"Cancer Med."},{"key":"3013_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s12185-019-02704-z","volume":"110","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, et al. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Int J Hematol. 2019;110:466\u201373.","journal-title":"Int J Hematol."},{"key":"3013_CR18","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41375-019-0480-2","volume":"33","author":"P Moreau","year":"2019","unstructured":"Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, et al. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m2 vs twice-weekly 27 mg\/m2 carfilzomib (randomized A.R.R.O.W. study). Leukemia. 2019;33:2934\u201346.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03013-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-03013-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03013-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:16:11Z","timestamp":1744179371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-03013-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["3013"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03013-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. N. Takezako, Dr. H. Handa, Dr. S. Ozaki, Dr. Ilseung Choi, Dr. T Miyamoto, and Dr. S. Hagiwara report grants and personal fees from Ono Pharmaceutical during the conduct of the study. Dr. T Miyamoto reports lecture fees from Bristol-Myers Squibb, Otsuka Pharmaceutical, MSD, Astellas Pharmaceutical, Astellas Amgen Pharmaceutical, Celgene, Abbvie Pharmaceutical, and Takeda Pharmaceutical. Dr. H. Shibayama reports grants and personal fees from Ono Pharmaceutical during the conduct of the study; grants from Astellas, Teijin, Shionogi, Taiho, Merck Sharp & Dohme, and Sumitomo Dainippon; grants and personal fees from Eisai, Celgene, Takeda, Nippon Shinyaku, and Daiichi Sankyo; and personal fees from Novartis, Janssen, Chugai, Kyowa Kirin, Otsuka, Bristol-Myers Squibb, Pfizer, Fujimoto Pharmaceutical, AbbVie, and AstraZeneca outside the submitted work. Dr. K. Suzuki reports grants and personal fees from Ono Pharmaceutical during the conduct of the study; grants and personal fees from Bristol-Myers Squibb, Celgene, and Amgen; and personal fees from Janssen, Takeda, Novartis, Sanofi, and AbbVie outside the submitted work. Dr. H. Kosugi reports grants and personal fees from Ono during the conduct of the study; and personal fees from Chugai, Celgene, Novartis, Bioverative Japan, Merck Sharp & Dohme, Takeda, Janssen, Japan Blood Products Organization, Bristol-Myers Squibb, and Ono Pharmaceutical outside the submitted work. Dr. M. Ri reports grants and personal fees from Ono Pharmaceutical during the conduct of the study; grants and personal fees from Celgene, Janssen, Takeda, Ono Pharmaceutical, Bristol-Myers Squibb, and Sanofi; and grants from Kyowa Kirin outside the submitted work. Dr. I. Sugiura reports no conflict of interest. Dr. S. Iida reports grants and personal fees from Ono Pharmaceutical during the conduct of the study; grants and personal fees from Takeda, Celgene, Janssen, Bristol-Myers Squibb, Daiichi Sankyo, Sanofi, and AbbVie; and grants from Merck Sharp & Dohme, Gilead, and GlaxoSmithKline outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}